Israeli Patent Office Allows Poolbeg Pharma's Application for Cytokine Release Syndrome Therapy

05:54 AM EDT, 07/21/2026 (MT Newswires) -- Poolbeg Pharma (POLB.L) received a notice of allowance from the Israeli patent office for its patent application covering POLB 001, its preventative therapy for cancer immunotherapy-induced cytokine release syndrome. The clinical-stage biopharmaceutical company said Tuesday that the application is expected to proceed to formal grant in due course. The notice of allowance follows a regulatory decision to grant the patent application in Europe and formal patent grants in Australia and Canada.